TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01693185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: continuous infusion 0.4 mcg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: bolus injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: bolus injection for 30 sec 1.0 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo (for remifentanil)
Description: normal saline mimic diluted remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (for midazolam)
Description: normal saline mimic to midazolam injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (for meperidine)
Description: normal saline mimic meperidine injection
Study: NCT03079973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-3073 (calcipotriene 0.005%)
Description: Topical solution P-3073 (calcipotriene 0.005%) once daily for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of P-3073
Description: Once daily for 24 weeks.
Study: NCT02283580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single limb
Description: Low load, high-repetitive resistance training.~* single limb at a time (e.g., one arm or one leg)~* elastic bands~* 8 weeks~* 3 times/week,~* each session 60 minutes~* seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~* maximal number of repetitions (RM) \* 3 sets in each exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two limb
Description: Low load, high-repetitive resistance training.~* two limbs at a time (e.g., both arms or both legs)~* elastic bands~* 8 weeks~* 3 times/week,~* each session 60 minutes~* seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~* maximal number of repetitions (RM) \* 3 sets in each exercise.
Study: NCT01758718

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eyelash line resection
Description: Eyelash resection surgery was performed for entropion with Down's syndrome
Study: NCT00461097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Egg oral immunotherapy
Description: Egg white solid powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Placebo for egg white solid
Study: NCT01851980

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CWS
Description: Chest wall strapping to reduced vital capacity by 20% of its baseline value

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CWS
Description: Chest wall strapping to reduced vital capacity by 20% of its baseline value

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CWS
Description: Chest wall strapping to reduced vital capacity by 20% of its baseline value

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 40 mg and 120 mg
Study: NCT00027703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT01851980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 40 mg and 120 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study: NCT01350375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT01955317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand cleansing with chlorhexidine
Description: Pregnant women in the intervention arm will receive an intensive hand cleansing promotion delivered at 3 in-home visits between one month prenatal and 1 week post natal. The intervention will promote and discuss with mothers the benefits of hand cleansing with chlorhexidine before breastfeeding, before umbilical cord care, after contact with respiratory secretions, and the convenience of using a waterless hand sanitizer especially during the neonatal period. Each mother will receive a half-liter pump bottle with chlorhexidine lotion. The program will also educate mothers about infectious causes of morbidity and mortality in neonates and promote understanding of the risk to the neonate from these diseases.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mother and neonatal health counselling
Description: This arms will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
Study: NCT02205697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation intention
Description: The intervention consists of an implementation intention whereby subjects create a unique plan to increase their fruit and vegetable intake by planning the where, when, and what to increase their fruit and vegetable intake.
Study: NCT03788980

Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: Patients will undergo a surgery called carotid endarterectomy where a surgeon will remove material that causes carotid stenosis (i.e. plaque)

Intervention type: DIAGNOSTIC_TEST
Intervention: Mini Mental Status Examination
Description: Short questionnaire used to diagnose cognitive dysfunction
Study: NCT01074255

Intervention type: DRUG
Intervention: EMEND
Description: EMEND (Aprepitant,125 mg oral capsules) is administered 1 hour prior to chemotherapy on treatment Day 1. EMEND (80 mg) is administered on the morning of Days 2 and 3. EMEND is concomitantly administered with a regimen of a corticosteroid and a 5-HT3 antagonist.
Study: NCT00027703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT01125813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant Factor VIII
Description: intravenous infusion of factor FVIII every other day.
Study: NCT03530319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
Study: NCT03024827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CanniMed® 1:20
Description: A cannabidiol (CBD): tetrahydrocannabinol (Δ9 THC) 20:1 ratio product will be provided as an oil-based suspension.
Study: NCT04126317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Intravitreally (IVT) administered as a liquid formulation in a vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose aflibercept
Description: Intravitreally (IVT) administered as a liquid formulation in a vial
Study: NCT04649970

Intervention type: PROCEDURE
Intervention: Antegrade double-J stent
Description: After exchanging the nephrostomy catheter over the J-tipped guidewire, 5 F multipurpose (45° tip) diagnostic vascular catheter was inserted. Once the pelvi¬ureteric junction was crossed and the ureter accessed, a straight hydrophilic guidewire and a catheter were used. Then, the cath-eter was advanced into the bladder over the wire, this guidewire was exchanged for an ultra-stiff guidewire, an 8 or 10 F double J ureteral stent was placed over the guidewire, and the safety kit of the stent was removed. A final fluoroscopic image was stored for correcting the stent position.
Study: NCT00027703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01477736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: 5 mg of immediate-release oxybutynin orally 3 times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: 5 mg of immediate-release oxybutynin orally 3 times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Description: 300 U intradetrusor injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Description: 300 U intradetrusor injection
Study: NCT02893098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humia inj.
Description: Single injection of 3mL Humia inj.~Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High hyal Plus inj.
Description: Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks
Study: NCT01491906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging and Behavior Counseling
Description: Participants randomized to the intervention arm will receive a series of components, delivered over 6 months: personalized behavior change goals to be self-monitored via text messaging, group starter counseling sessions, and personalized individual counseling. Each participant will also receive a pedometer to facilitate self-monitoring.
Study: NCT02468908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02530788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selenium Supplement (sodium selenite)
Description: On the evening before operation the patient receives the first dosage of Selenium (300µg orally) orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives 3000µg Selenium as sodium selenite (selenase® T) intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the evening before operation the patient receives the first dosage of placebo orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives placebo intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets placebo intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives placebo intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD).
Study: NCT04458818

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolene Mesh Vocal Cord Medialization Implant
Description: The surgery will be performed under local anesthesia (lignocaine with adrenaline 2%) and procedural sedation with propofol 25-100mcg/kg/min (only sedative dose) will be administered, so that the patient remains vocally responsive during the procedure. Incision will be made at the lower border of thyroid cartilage under aseptic measures. Skin flaps will be raised in sub-platysmal plane, strap muscles will be separated in the midline to expose the laryngeal cartilaginous framework. A simple laryngeal window approach will be used to place the Ethicon prolene mesh 6 x 6cm Swiss roll, secured with prolene 2/0 suture trimmed to the required size. Post op voice analysis will be done on 7th day and 14th post-operative day. Monthly follow up will be advised after that.
Study: NCT00715689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study: NCT01440010

Intervention type: RADIATION
Intervention: IORT with 50 kV x-rays, 20 Gy
Description: Intraoperative radiotherapy with the INTRABEAM System with 20 Gy
Study: NCT03062085

Intervention type: OTHER
Intervention: Cataract
Description: The genetic and environmental factors concerning to the pathogenesis of cataract in the three groups.

Intervention type: OTHER
Intervention: Cataract
Description: The genetic and environmental factors concerning to the pathogenesis of cataract in the three groups.

Intervention type: OTHER
Intervention: Cataract
Description: The genetic and environmental factors concerning to the pathogenesis of cataract in the three groups.
Study: NCT03041298

Intervention type: PROCEDURE
Intervention: MR mammography with Dotarem
Study: NCT04089072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Prior to the initiation of the randomized treatment, the subject will have received 2 vasopressors ( norepinephrine and vasopressin), they will be initiated on IV hydrocortisone . Once the patient is unable to maintain a mean arterial pressure of \>65mmHg and the hydrocortisone has been administered there will be an addition of a third-line vasopressor.~Patients enrolled in the intervention group will receive ProvayBlue® and Patients enrolled in the control group will receive Phenylephrine infusion as a third line vasopressor in the treatment of septic shock.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Prior to the initiation of the randomized treatment, the subject will have received 2 vasopressors ( norepinephrine and vasopressin) already , they will be initiated on IV hydrocortisone . Once the patient is unable to maintain a mean arterial pressure of \>65mmHg and the hydrocortisone has been administered there will be an addition of a third-line vasopressor.~Patients enrolled in the intervention group will receive ProvayBlue® and Patients enrolled in the control group will receive Phenylephrine infusion as a third line vasopressor in the treatment of septic shock.
Study: NCT00889967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin for Inhalation
Description: 100 mg once daily by inhalation for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin for Inhalation
Description: 150 mg once daily by inhalation for 28 days
Study: NCT00966901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: 25 mg nicotine patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: As a positive control, a placebo patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No Patch Control
Description: As a negative control, a marked site on the lower back or buttock was assigned as test area, but no patch was applied.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVA and UVB irradiation
Description: All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
Study: NCT01915771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide
Description: 20 mg dose
Study: NCT02252926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 25 mg bupivacaine lozenge

Intervention type: DRUG
Group type: OTHER
Intervention: Standard treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin)
Description: Standard treatment includes lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin
Study: NCT03494244

Intervention type: PROCEDURE
Intervention: Direct-to-implant breast reconstruction
Description: Terminal prosthetic implanted at the time of mastectomy.
Study: NCT00889967

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily by inhalation for 28 days
Study: NCT02504749

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anasthesia,spinal anasthesia
Description: Randomization done by computer generated random number in sealed opaque envolopes.Each patient was given a study information sheet and a consent was signed. Sample size was calculated to prevent type II error. Based on these data, we would need to study 225 cases in each arm to be able to reject the null hypothesis that the rates for the experimental and control groups are equal with a probability of 80%. The type I error probability associated with this test for the null hypothesis is 0.05. We used an uncorrected chi-squared statistic to evaluate this null hypothesis. Additionally, to compensate for discontinuations, we recruited 225 women in each arm.~450-pregnant women with an indication for caesarean section were randomly allocated .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anasthesia,spinal anasthesia
Description: Randomization done by computer generated random number in sealed opaque envolopes.Each patient was given a study information sheet and a consent was signed. Sample size was calculated to prevent type II error. Based on these data, we would need to study 225 cases in each arm to be able to reject the null hypothesis that the rates for the experimental and control groups are equal with a probability of 80%. The type I error probability associated with this test for the null hypothesis is 0.05. We used an uncorrected chi-squared statistic to evaluate this null hypothesis. Additionally, to compensate for discontinuations, we recruited 225 women in each arm.~450-pregnant women with an indication for caesarean section were randomly allocated .
Study: NCT03494244

Intervention type: PROCEDURE
Intervention: Direct-to-implant breast reconstruction
Description: Terminal prosthetic implanted at the time of mastectomy.

Intervention type: DEVICE
Intervention: Acellular dermal matrix
Description: Banked tissue used to support the directly implanted breast prosthesis.
Study: NCT02593955

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PD exercise
Description: Supervised high intensity exercise 3x/week for 16 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: Sleep medicine physician will provide discuss sleep habits with participants, provide tips for improving sleep hygiene, and provide reading materials.
Study: NCT04165096

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boserolimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Description: PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-0482
Description: IV infusion
Study: NCT00575510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Multiple component intervention based in the unified theory of behavior

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Partial intervention (full intervention minus cultural-specific component)
Study: NCT00886964

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal HBV 1 course
Description: Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular HBV I course
Description: Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months